310 related articles for article (PubMed ID: 8021923)
1. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
[TBL] [Abstract][Full Text] [Related]
2. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.
Durroux T; Peter M; Turcatti G; Chollet A; Balestre MN; Barberis C; Seyer R
J Med Chem; 1999 Apr; 42(7):1312-9. PubMed ID: 10197974
[TBL] [Abstract][Full Text] [Related]
4. A radioiodinated linear vasopressin antagonist: a ligand with high affinity and specificity for V1a receptors.
Schmidt A; Audigier S; Barberis C; Jard S; Manning M; Kolodziejczyk AS; Sawyer WH
FEBS Lett; 1991 Apr; 282(1):77-81. PubMed ID: 1827414
[TBL] [Abstract][Full Text] [Related]
5. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe.
Arsenijevic Y; Dubois-Dauphin M; Tribollet E; Manning M; Sawyer WH; Dreifuss JJ
J Endocrinol; 1994 Jun; 141(3):383-91. PubMed ID: 8071638
[TBL] [Abstract][Full Text] [Related]
8. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
[TBL] [Abstract][Full Text] [Related]
9. Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists.
Howl J; Yarwood NJ; Stock D; Wheatley M
Neuropeptides; 1996 Feb; 30(1):73-9. PubMed ID: 8868303
[TBL] [Abstract][Full Text] [Related]
10. Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.
Manning M; Klis WA; Kruszynski M; Przybylski JP; Olma A; Wo NC; Pelton GH; Sawyer WH
Int J Pept Protein Res; 1988 Dec; 32(6):455-67. PubMed ID: 3246475
[TBL] [Abstract][Full Text] [Related]
11. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.
Barbeis C; Balestre MN; Jard S; Tribollet E; Arsenijevic Y; Dreifuss JJ; Bankowski K; Manning M; Chan WY; Schlosser SS
Neuroendocrinology; 1995 Aug; 62(2):135-46. PubMed ID: 8584113
[TBL] [Abstract][Full Text] [Related]
13. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
Manning M; Stoev S; Kolodziejczyk A; Klis WA; Kruszynski M; Misicka A; Olma A; Wo NC; Sawyer WH
J Med Chem; 1990 Nov; 33(11):3079-86. PubMed ID: 2231609
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
15. Efficient photoaffinity labeling of the rat V1a vasopressin receptor using a linear azidopeptidic antagonist.
Carnazzi E; Aumelas A; Phalipou S; Mouillac B; Guillon G; Barberis C; Seyer R
Eur J Biochem; 1997 Aug; 247(3):906-13. PubMed ID: 9288914
[TBL] [Abstract][Full Text] [Related]
16. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin and oxytocin receptors on plasma membranes from rat mammary gland. Demonstration of vasopressin receptors by stimulation of inositol phosphate formation, and oxytocin receptors by binding of a specific 125I-labeled oxytocin antagonist, d(CH2)5(1)[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT.
Soloff MS; Fernström MA; Fernström MJ
Biochem Cell Biol; 1989; 67(2-3):152-62. PubMed ID: 2546575
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
Ammar A; Roseau S; Butlen D
Am J Physiol; 1992 Apr; 262(4 Pt 2):F546-53. PubMed ID: 1533099
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
Thibonnier M; Auzan C; Madhun Z; Wilkins P; Berti-Mattera L; Clauser E
J Biol Chem; 1994 Feb; 269(5):3304-10. PubMed ID: 8106369
[TBL] [Abstract][Full Text] [Related]
20. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
